Expert perspectives on the introduction of Triple Artemisinin-based Combination Therapies (TACTs) in Southeast Asia: a Delphi study.
Delphi study
Drug resistance
Expert perspectives
Malaria
Triple artemisinin-based combination therapies
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
30 04 2022
30 04 2022
Historique:
received:
03
01
2022
accepted:
07
04
2022
entrez:
30
4
2022
pubmed:
1
5
2022
medline:
4
5
2022
Statut:
epublish
Résumé
Triple Artemisinin-based Combination Therapies (TACTs) are being developed as a response to artemisinin and partner drug resistance in Southeast Asia. However, the desirability, timing and practical feasibility of introducing TACTs in Southeast Asia is subject to debate. This study systematically assesses perspectives of malaria experts towards the introduction of TACTs as first-line treatment for uncomplicated falciparum malaria in Southeast Asia. A two-round Delphi study was conducted. In the first round, 53 malaria experts answered open-ended questions on what they consider the most important advantages, disadvantages, and implementation barriers for introducing TACTs in Southeast Asia. In the second round, the expert panel rated the relevance of each statement on a 5-point Likert scale. Malaria experts identified 15 advantages, 15 disadvantages and 13 implementation barriers for introducing TACTs in Southeast Asia in the first round of data collection. In the second round, consensus was reached on 13 advantages (8 perceived as relevant, 5 as not-relevant), 12 disadvantages (10 relevant, 2 not-relevant), and 13 implementation barriers (all relevant). Advantages attributed highest relevance related to the clinical and epidemiological rationale of introducing TACTs. Disadvantages attributed highest relevance related to increased side-effects, unavailability of fixed-dose TACTs, and potential cost increases. Implementation barriers attributed highest relevance related to obtaining timely regulatory approval, timely availability of fixed-dose TACTs, and generating global policy support for introducing TACTs. The study provides a structured oversight of malaria experts' perceptions on the major advantages, disadvantages and implementation challenges for introducing TACTs in Southeast Asia, over current practices of rotating ACTs when treatment failure is observed. The findings can benefit strategic decision making in the battle against drug-resistant malaria.
Sections du résumé
BACKGROUND
Triple Artemisinin-based Combination Therapies (TACTs) are being developed as a response to artemisinin and partner drug resistance in Southeast Asia. However, the desirability, timing and practical feasibility of introducing TACTs in Southeast Asia is subject to debate. This study systematically assesses perspectives of malaria experts towards the introduction of TACTs as first-line treatment for uncomplicated falciparum malaria in Southeast Asia.
METHODS
A two-round Delphi study was conducted. In the first round, 53 malaria experts answered open-ended questions on what they consider the most important advantages, disadvantages, and implementation barriers for introducing TACTs in Southeast Asia. In the second round, the expert panel rated the relevance of each statement on a 5-point Likert scale.
RESULTS
Malaria experts identified 15 advantages, 15 disadvantages and 13 implementation barriers for introducing TACTs in Southeast Asia in the first round of data collection. In the second round, consensus was reached on 13 advantages (8 perceived as relevant, 5 as not-relevant), 12 disadvantages (10 relevant, 2 not-relevant), and 13 implementation barriers (all relevant). Advantages attributed highest relevance related to the clinical and epidemiological rationale of introducing TACTs. Disadvantages attributed highest relevance related to increased side-effects, unavailability of fixed-dose TACTs, and potential cost increases. Implementation barriers attributed highest relevance related to obtaining timely regulatory approval, timely availability of fixed-dose TACTs, and generating global policy support for introducing TACTs.
CONCLUSIONS
The study provides a structured oversight of malaria experts' perceptions on the major advantages, disadvantages and implementation challenges for introducing TACTs in Southeast Asia, over current practices of rotating ACTs when treatment failure is observed. The findings can benefit strategic decision making in the battle against drug-resistant malaria.
Identifiants
pubmed: 35490212
doi: 10.1186/s12889-022-13212-x
pii: 10.1186/s12889-022-13212-x
pmc: PMC9055751
doi:
Substances chimiques
Antimalarials
0
Artemisinins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
864Informations de copyright
© 2022. The Author(s).
Références
Environ Innov Soc Transit. 2021 Sep;40:40-59
pubmed: 35106274
BMC Med Educ. 2021 Nov 12;21(1):572
pubmed: 34772401
Cold Spring Harb Perspect Med. 2017 Jul 5;7(7):
pubmed: 28289248
BMC Health Serv Res. 2011 Nov 16;11:312
pubmed: 22087801
Malar J. 2013 Feb 21;12:68
pubmed: 23433060
Clin Infect Dis. 2016 Sep 15;63(6):784-791
pubmed: 27313266
PLoS One. 2011 Feb 24;6(2):e17439
pubmed: 21390277
BMC Infect Dis. 2014 May 16;14:268
pubmed: 24884569
Palliat Med. 2017 Sep;31(8):684-706
pubmed: 28190381
Malar J. 2019 Jun 20;18(1):203
pubmed: 31221145
Health Policy Plan. 2012 Dec;27(8):677-86
pubmed: 22460007
Malar J. 2019 Oct 11;18(1):338
pubmed: 31581941
PLoS One. 2014 Apr 03;9(4):e93763
pubmed: 24699934
Malar J. 2011 Oct 31;10:328
pubmed: 22039922
Malar J. 2019 Oct 3;18(1):339
pubmed: 31581951
PLoS Comput Biol. 2021 Mar 25;17(3):e1008850
pubmed: 33764971
Epilepsy Behav. 2017 Dec;77:79-89
pubmed: 29127865
Malar J. 2017 Apr 25;16(1):173
pubmed: 28441956
Malar J. 2013 Jun 19;12:211
pubmed: 23782869
PLoS One. 2021 Feb 2;16(2):e0246273
pubmed: 33529197
Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):193-7
pubmed: 18165492
Malar J. 2007 Mar 16;6:31
pubmed: 17367518
Malar J. 2016 Apr 08;15:194
pubmed: 27059952
BMC Med Res Methodol. 2020 Jun 15;20(1):156
pubmed: 32539717
Malar J. 2008 May 29;7:96
pubmed: 18510724
Malar J. 2011 Oct 31;10:326
pubmed: 22039838
Trends Parasitol. 2021 Jan;37(1):15-24
pubmed: 33060063
Malar J. 2017 Apr 25;16(1):171
pubmed: 28438204
Health Policy Plan. 2004 Nov;19(6):356-70
pubmed: 15459161
Malar J. 2015 May 30;14:224
pubmed: 26024880
Malar J. 2015 Oct 09;14:398
pubmed: 26452625
Trop Med Int Health. 2006 Apr;11(4):452-61
pubmed: 16553928
BMC Med Res Methodol. 2018 Nov 15;18(1):134
pubmed: 30442099
Nat Rev Drug Discov. 2015 Jun;14(6):424-42
pubmed: 26000721
PLoS Negl Trop Dis. 2018 Oct 4;12(10):e0006497
pubmed: 30286085
Int Health. 2015 Jul;7(4):239-46
pubmed: 25855638
Lancet. 2020 Apr 25;395(10233):1345-1360
pubmed: 32171078
Lancet Infect Dis. 2019 Sep;19(9):952-961
pubmed: 31345710
Trends Parasitol. 2017 Mar;33(3):175-184
pubmed: 27727128
Malar J. 2017 May 2;16(1):180
pubmed: 28464945
Malar J. 2016 Dec 6;15(1):585
pubmed: 27919257
J Adv Nurs. 2000 Oct;32(4):1008-15
pubmed: 11095242
Lancet. 2021 Dec 19;396(10267):1976
pubmed: 33341138
Philos Trans R Soc Lond B Biol Sci. 1999 Apr 29;354(1384):739-49
pubmed: 10365399
Malar J. 2011 Aug 18;10:243
pubmed: 21851625
Malar J. 2014 Nov 23;13:452
pubmed: 25418416
PLoS One. 2021 Aug 31;16(8):e0256567
pubmed: 34464398
Malar J. 2007 May 29;6:72
pubmed: 17535417
Trends Parasitol. 2017 May;33(5):353-363
pubmed: 28187990
Malar J. 2011 May 23;10:143
pubmed: 21605364
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0112121
pubmed: 34516247
Malar J. 2017 Nov 13;16(1):460
pubmed: 29132370
Lancet. 2004 Jan 17;363(9404):237-40
pubmed: 14738799
Afr J AIDS Res. 2014 Sep;13(3):291-303
pubmed: 25388983